These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intensive lipid lowering with atorvastatin in coronary disease. Modest GA N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003833 [No Abstract] [Full Text] [Related]
4. Cholesterol. Harv Mens Health Watch; 2006 Aug; 11(1):2-3. PubMed ID: 17111473 [No Abstract] [Full Text] [Related]
5. All at sea: new lipid-lowering drug trials continue to disappoint. Wierzbicki AS Int J Clin Pract; 2013 Jul; 67(7):595-8. PubMed ID: 23758438 [No Abstract] [Full Text] [Related]
6. [Lipid lowering by rosuvastatin: how do statins differ?]. Laufs U Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669 [No Abstract] [Full Text] [Related]
7. Achieving vascular risk factor targets: a survey of a London general practice. Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M Angiology; 2008; 59(1):36-46. PubMed ID: 18319220 [TBL] [Abstract][Full Text] [Related]
8. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins. Barter PJ; Rye KA Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953 [No Abstract] [Full Text] [Related]
9. Achieving lipid goals. A study of outcomes in an NP Clinic. Adkins J; Stanley M Adv Nurse Pract; 2007 Jun; 15(6):61-2, 64. PubMed ID: 19999011 [No Abstract] [Full Text] [Related]
10. Stricter cholesterol guidelines broaden indications for the 'statin' drugs. Capriotti T Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600 [No Abstract] [Full Text] [Related]
11. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801 [TBL] [Abstract][Full Text] [Related]
12. Are we lowering LDL cholesterol sufficiently? Barter P; Rye KA Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):290-1. PubMed ID: 16728988 [No Abstract] [Full Text] [Related]
13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
14. [Reasons for a combination]. Núñez-Cortés JM Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547 [No Abstract] [Full Text] [Related]
15. [Paradigm shift with the new American guidelines for lipid-lowering therapy]. Hjemdahl P; Andersén-Karlsson E Lakartidningen; 2014 Apr 2-8; 111(14):596-7. PubMed ID: 24779174 [No Abstract] [Full Text] [Related]
16. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Rosenson RS Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615 [TBL] [Abstract][Full Text] [Related]